Skip to content
Triangle logo TriangleGet started
← Study library

NCT02858258 · CITED IN SOURCE DOCUMENTS

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
UNKNOWN
Registry last update
2017-12-19

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: All patients must meet the following criteria: * Histologically confirmed diagnosis of MCL according to WHO classification * suitable for high-dose treatment including high-dose Ara-C * Stage II-IV (Ann Arbor) * Age ≥ 18 years and ≤ 65 years * Previously untreated MCL * At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations. * ECOG/WHO performance status ≤ 2 * The following laboratory values at screening (unless related to MCL): * Absolute neutrophil count (ANC) ≥1000 cells/µL * Platelets ≥100,000 cells/µL * Transaminases (AST and ALT) ≤3 x upper limit of normal (ULN) * Total bilirubin ≤2 x ULN unless due to known Morbus Meulengracht \[Gilbert-Meulengracht-Syndrome\]) * Creatinine ≤2 mg/dL or calculated creatinine clearance ≥ 50 mL/min * Written informed consent form according to ICH/EU GCP and national regulations * Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug. Exclusion Criteria: Any potential subject who meets any of the following criteria will be excluded from participating in the study. * Major surgery within 4 weeks prior to randomization. * Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg phenprocoumon). * History of stroke or intracranial hemorrhage within 6 months prior to randomization. * Requires treatment with strong CYP3A4/5 inhibitors. * Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk. * Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization. * Known CNS involvement of MCL * Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation) * Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies * Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy according to trial protocol * Serious concomitant disease interfering with a regular therapy according to the study protocol: * Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN ) * Pulmonary (e.g. chronic lung disease with hypoxemia) * Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus) * Renal insufficiency (unless caused by the lymphoma): creatinine \> 2x normal value and/or creatinin clearance \< 50 ml/min) * Impairment of liver function (unless caused by the lymphoma): transaminases \> 3x normal or bilirubin \> 2,0 mg/dl unless due to morbus Meulengracht (Gilbert-Meulengracht-Syndrome) * Patients with unresolved hepatitis B or C infection or known HIV positive infection (mandatory test) * Prior organ, bone marrow or peripheral blood stem cell transplantation * Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer * Pregnancy or lactation * Any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule * Subjects not able to give consent * Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial * Participation in another clinical trial within 30 days before randomization in this study.
healthy Volunteers
false
maximum Age
65 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM
    intervention Names
    1. Drug: R-CHOP/R-DHAP
    2. Drug: ASCT conditioning
    label
    Standard Arm A
    type
    ACTIVE_COMPARATOR
  2. description
    R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)
    intervention Names
    1. Drug: R-CHOP/R-DHAP
    2. Drug: Ibrutinib (Induction)
    3. Drug: ASCT conditioning
    4. Drug: Ibrutinib (Maintenance)
    label
    Experimental Arm A+I
    type
    EXPERIMENTAL
  3. description
    R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)
    intervention Names
    1. Drug: R-CHOP/R-DHAP
    2. Drug: Ibrutinib (Induction)
    3. Drug: Ibrutinib (Maintenance)
    label
    Experimental Arm I
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Experimental Arm A+I
    2. Experimental Arm I
    3. Standard Arm A
    description
    Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
    name
    R-CHOP/R-DHAP
    other Names
    1. rituximab, CHOP, DHAP
    type
    DRUG
  2. arm Group Labels
    1. Experimental Arm A+I
    2. Experimental Arm I
    description
    Ibrutinib: only in cycle 1,3,5 on Day 1-19
    name
    Ibrutinib (Induction)
    other Names
    1. Imbruvica
    type
    DRUG
  3. arm Group Labels
    1. Experimental Arm A+I
    2. Standard Arm A
    description
    ASCT conditioning THAM or BEAM, stratified per site before trial activation at site THAM (TBI (total body irradiation), Ara-C, Melphalan) or BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
    name
    ASCT conditioning
    other Names
    1. THAM or BEAM
    type
    DRUG
  4. arm Group Labels
    1. Experimental Arm A+I
    2. Experimental Arm I
    description
    Ibrutinib (Maintenance), daily 560 mg for 2 years;
    name
    Ibrutinib (Maintenance)
    other Names
    1. Imbruvica
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
870
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Failure Free Survival
    time Frame
    From start of treatment until stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause, whichever comes first, assessed up to 120 months.
secondary Outcomes
  1. measure
    Overall Survival
    time Frame
    From start of treatment until the date of first documented progression, assessed up to 120 months.
  2. description
    Safety and tolerability
    measure
    Number of participants with treatment-related adverse events as assessed by CTC Version 4.03
    time Frame
    From start of Ibrutinib treatment during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints. Through study conduction, an average of up to 30 months.
  3. measure
    Progression-free survival (PFS)
    time Frame
    PFS is the time to progression or death from any cause. Assed up to 120 months.
  4. description
    Toxicity Endpoints
    measure
    Number of Secondary Primary Malignancies
    time Frame
    From start of treatment through the study conduction, up to 120 months.
  5. description
    Toxicity Endpoints
    measure
    Number of Adverse Events by CTC grade (Version 4.03)
    time Frame
    From start of treatment through the study conduction, up to 120 months.
Full study description
brief Summary
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
detailed Description
Objectives and Endpoints Primary Objective: To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP+ibrutinib /R-DHAP followed by ASCT and ibrutinib maintenance experimental arm A+I), and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance experimental arm I) as future standard based on the comparison of the investigator-assessed failure-free survival (FFS). Secondary Objectives: * To compare the efficacy of the three treatment arms in terms of secondary efficacy endpoints * To determine the safety and tolerability of ibrutinib during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints Primary Endpoint: FFS defined as time from start of treatment to stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause. Secondary Efficacy Endpoints: * Overall survival (OS) * Progression-free survival (PFS) from randomization, from end of induction immuno-chemotherapy in patients with CR or PR at end of induction immuno-chemotherapy, and from the staging 6 weeks after end of induction assessment (at month 6) * Overall response and complete remission rates at midterm, at end of induction, 3 months after end of induction immunochemotherapy (at month 6) * PR to CR conversion rate during follow-up after end of induction immuno-chemotherapy Secondary Toxicity Endpoints: * Rates of AEs, SAEs, and SUSARs by CTC grade (Version 4.03) during induction immuno-chemotherapy and during periods of follow-up after response to immune-chemotherapy * Cumulative incidence rates of SPMs Exploratory Objectives: * To compare feasibility of ASCT in arm A+I vs. arm A * To compare minimal residual disease status between the three treatment groups * To determine the impact of ibrutinib during induction immuno-chemotherapy and during maintenance therapy on the minimal residual disease status * To determine the prognostic value of minimal residual disease status * To determine the prognostic value of positron emission tomography with fluorine 18-fluorodeoxyglucose * To determine clinical and biological prognostic and predictive factors * To determine the role of total body irradiation (TBI) in ASCT conditioning Exploratory Endpoints: * Rate of successful stem cell mobilisations (success: separation of at least 2x2x10(6) CD34-positive cells, including a back-up) * Rate of molecular remissions (MRD-negative patients) at midterm, at end of induction immuno-chemotherapy, and at staging time-points during follow-up in patients with remission after end of induction immuno-chemotherapy * Time to molecular remission from start of therapy * Time to molecular relapse for patients in clinical and molecular remission after end of induction immunochemotherapy * RD in FDG-PET negative or positive patients after induction and ASCT Exploratory objectives may be evaluated only in a subset of patients according to local standards and resources.
Source references
references
  1. citation
    Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Shpilberg O, da Silva MG, Leppa S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Hess G, Meerten TV, Wirths S, Herhaus P, Novak U, Dierlamm J, Hanel M, Hanoun C, Sonnevi K, Visco C, Donnarumma D, Ferreri AJM, Patti C, Stefani PM, Pott C, Klapper W, Schmidt C, Unterhalt M, Tix T, Ladetto M, Hoster E; European Mantle Cell Lymphoma Network. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. Lancet. 2026 May 16;407(10542):1953-1967. doi: 10.1016/S0140-6736(26)00362-4.
    pmid
    42134356
    type
    DERIVED
  2. citation
    Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppa S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hanel M, Dierlamm J, Pott C, Klapper W, Gozel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.
    pmid
    38705160
    type
    DERIVED
  3. citation
    Kumar A. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma? Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):155-162. doi: 10.1182/hematology.2022000333.
    pmid
    36485104
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-a5134b11b56d51bc1e7c
      requested nct id
      NCT02858258
      primary nct id
      NCT02858258
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      4707248828af702722bbe7b201c976bdb098b2c3330d18f3733fcc645bbd9e12
      payload sha256
      877f3c3203bcdaca5bf50191f982977c0e3684e12fd210477a705beff50dc5b2
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-a5134b11b56d51bc1e7c
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT02858258
      occurrences
      1. context exact
        options to avoid autologous SCT consolidation):</p> <div class="pdq-content-list"><ol id="_2320"><li>The prospective, randomized <a href="/clinicaltrials/NCT02858258">TRIANGLE</a> trial (NCT02858258) trial included 870 patients aged 65 years or younger with previously untreated MCL who were fit enough for autologous SCT. Th
        end
        76922
        exact text
        NCT02858258
        start
        76911
      2. context exact
        onsolidation):</p> <div class="pdq-content-list"><ol id="_2320"><li>The prospective, randomized <a href="/clinicaltrials/NCT02858258">TRIANGLE</a> trial (NCT02858258) trial included 870 patients aged 65 years or younger with previously untreated MCL who were fit enough for autologous SCT. There were three study arms. The pr
        end
        76955
        exact text
        NCT02858258
        start
        76944
      3. context exact
        nce A1</a>]</li></ul></div></li><li>As <a href="/types/lymphoma/hp/mantle-cell-lymphoma-treatment#_2320">previously described</a>, the <a href="/clinicaltrials/NCT02858258">TRIANGLE</a> trial (NCT02858258) was a prospective randomized trial that included 870 patients aged 65 years or younger with previously untreated MCL who were
        end
        112705
        exact text
        NCT02858258
        start
        112694
      4. context exact
        li>As <a href="/types/lymphoma/hp/mantle-cell-lymphoma-treatment#_2320">previously described</a>, the <a href="/clinicaltrials/NCT02858258">TRIANGLE</a> trial (NCT02858258) was a prospective randomized trial that included 870 patients aged 65 years or younger with previously untreated MCL who were transplant-eligible.[<a href="#c
        end
        112738
        exact text
        NCT02858258
        start
        112727
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/2b30507e0b5746e560.html
      source file sha256
      4707248828af702722bbe7b201c976bdb098b2c3330d18f3733fcc645bbd9e12
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:03.182346+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      83643bb6e898092f7ecda4e33f80a34aa56cece2dda57fab08650db99f6e11e3
      source title
      Mantle Cell Lymphoma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 12, 2025
        datetime
        2025-05-12T12:00:00Z
        display
        May 12, 2025

    Preserved source evidence · Not medical advice